Such specific ApoA-HDL shortage induced by NACT was also reported in other investigations during both neoadjuvant and adjuvant BC treatments that incorporated cytotoxic drugs such as anthracycline and paclitaxel [45,69,70,71]. The gene discussed is APOA1; the disease is breast cancer.